[20200527]IN11347_新冠肺炎的治疗：羟基氯喹和氯喹 .pdf

CRS INSIGHT Prepared for Members and Committees of Congress INSIGHTINSIGHTi i Treatment of COVID-19: Hydroxychloroquine and Chloroquine Updated May 27, 2020 To date, the U.S. Food and Drug Administration (FDA) has not approved any therapeuticsdrugs or biologicsfor the treatment of COVID-19. However, FDA has authorized the emergency use of three drugs, including two drugs that have been approved by FDA for other uses: hydroxychloroquine sulfate (“hydroxychloroquine”) and chloroquine phosphate (“chloroquine”). The agency authorized the emergency use of both drugs on March 28, 2020, determining that based on the totality of scientific evidence, “it is reasonable to believe that chloroquine and hydroxychloroquine may be effective in treating COVID-19,” and that when used in accord with the conditions of the emergency use authorization (EUA), the known and potential benefits outweigh the known and potential risks of these drugs. Some stakeholdersincluding several former FDA officialshave expressed concern regarding FDAs EUA, stating that current data regarding the safety and effectiveness of these drugs for treatment of COVID-19 are largely anecdotal and that expanding access may jeopar